We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I was there before the stellar rise so ****ed, but less. Yes, let's hope as I would like to at least break even here.
Lol...."SNG is doing not that bad"....ha ha ha....you tell that to the majority of punters who bought in £1 plus plus, £2 plus plus towards £3.....no one got in sub £1 ( or very few ) on the day of their stellar rise....in the meantime, let's hope SFX-01's phase2/3 efficacy assessment for Covid/Ards is a tad more conclusive than SNG's latest ambiguous results. Gla holders....Tick Tock. ;-)
There was a placing at 175 and as stagnated as it was, it definitely changed - not for the better as you can see. I was amazed by the price at the time but not anymore. Your point exactly? We need to meet in person one day so you’ll see how far for an hypocrite I am. I am still here reading how soon it will move on a daily basis.
In other words, please pipe down and stop being such a hypocrite.
I suspect the reason is similar to why someone would post "I am just amazed we're still under the 175p." or "the price of SNG is stagnated.. but sooner or later that will change." on the SNG thead?
I have over 100k shares since +3 years and my average is still higher than the current price which it’s undoubtedly “about to move”.
SNG is doing not that bad - unsure this was directed to me, if your average is in the mid 30s.
The idea behind this constant “about to move” is to drag in punters or just help the chat alive? There might be a reason.
Lol...and don't you get tired of hanging around share forums in different guises where you're not invested....ho ho ho....the sp moved from c3p to c 15p and back to c8p on £11m placing, and so the sp hasn't been standing still.....we're now awaiting the potential blockbuster RNS on SFX-01's Covid / Ards patinet trial.....if you want a bit of movement , postive efficacy data could send the sp off the scale....ha ha ha ha ....Gla Holders..Tick Tock!!! ;-)
How's SNG going? Still amazed it's only at 175p?
Don't you ever get tired of calling it wrong every single time? It's been a bout to move for like year or so.
Ps and it's not just the primary objectives that are crucial to proceedings , as the exploratory objectives could also be highly significant to Prof Chalmers assessment, and so hopefully a very positive and fully comprehensive efficacy report is heading our way....along with tremendous Transformational UPside!!! Gla ;-)
The trial will test the following hypothesis:
Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection).
.........................
Primary objective:
To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia. Outcome measure:7 point ordinal scale measured on Day 15.
Secondary Objectives:
Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19
Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm
Outcome measures:
Cumulative incidence of serious Adverse events (SAEs)
Discontinuation or temporary suspension of treatment
..............................
Exploratory objectives (All sites)
Biofire analysis of nasal swab or sputum sample
Subanalysis of outcomes according to the causative pathogen
Exploratory objectives (TAYSIDE ONLY)
Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells
Neutrophil functional studies in isolated cells
Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood
https://star-covid19.com/
Thank you for the reply...very helpful.
To anyone answering my questions, its quite okay to say "that's wrong and utter rubbish"...
If I am wondering then I am sure at least one other must be.
Thanks.
Yep, no doubt, but it's the collective data that matters, the condition of some on the placebo could have improved, but hopefully Prof Chalmers assessment will give a strong indication of efficacy from those who were administered SFX-01 , as it's an improvement of a certain percentage of those on SFX 01 against those on the placebo group which we're looking for, which appears to be one the problems experienced by SNG's recently reported phase 2 data, whereby no definitive conclusion could be made it seems because their patient groups came from those displaying mild symptoms at home, whereas as SFX 01's recruitment is made up from hospitalised patients , and so efficacy data should be much more likely to be observed. Gl :-)
Thanks again MM.
But seriously if you are having difficulty breathing and you get a pill to take and it helps you...that's a pretty big clue.
Or is that not the case?
That should read " so No one will know" :-)
It's a double blind, randomised, placebo-controlled study , and so one will know until the data is unblinded, which is the case now with Prof Chalmers current interim efficacy assessment....only Prof Chalmers and his close team will have access to the data initially. Gl :-)
With 100 patients and families, plus all the staff involved, how do you stop a leak of success or failure?
Everything firmly crossed for good news Prof Chalmers...can't be long now, although maybe a good sign that we're still waiting as I'm sure Huw would want any bad news out of the way by now, with so much potential material newsflow from the rest of the pipeline stacking up....Positive efficacy data from the Covid/Ards patient trial will be truly sensational....Bring it on!!! ;-)
Let's hope we get an upside rerate rather than a downside one. This is my second biggest investment after SNG and might soon be my biggest the way that one has been falling recently. I have taken enough of a big hit there already and am hoping this one can soon bring some cheers.
Remember the calibre of investors who recently bought in big at 8p
https://evgen.com/investors/shareholder-information/
If the MM's genuinely thought we had no chance of success and they were going to get a chance to crash the SP soon, they'd be trying to suck PI's in with a juicy-looking rise, not sticking to 8p and trying to bore us out.
Simply not enough investors interested yet. Nothing to do with the chancers of success.
Some big trades going through after hours... Time will be the judge if we have got it right....not the current Mcap.
GL,,,
My only concern is why are we still so undervalued at a point where we could literally be days away from transformational news not only for the company but for the entire world medical industry as a whole. It all makes for a bigger bang if/when good news lands but at the same time it does make me wonder.
Good luck all, tick tock tick tock
Hope so nolupus.
We should see some rerate here shortly
News can’t be far away now IMO